| Product Name | Mouse GAGs(Glycosaminoglycan) ELISA Kit |
|---|---|
| Alternative Names | Mucopolysaccharide; GAGs |
| 48T Price | 1820 |
|---|---|
| 96T Price | 2600 |
| 96T*5 Price | 11050 |
| Species | Mouse |
|---|---|
| Assay Type | Competitive Inhibition |
| Sensitivity | 0.51 ng/mL |
| Detection Range | 1.57-100 ng/mL |
| Sample Type | serum, plasma, cell lysates, cell culture supernates and other biological fluids |
| Assay Length | 2h |
| Research Area | Tumor immunity;Hepatology; |
|---|---|
| Test Principle | This assay employs the competitive inhibition enzyme immunoassay technique. The microtiter plate provided in this kit has been pre-coated with Mouse GAGs. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse GAGs. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse GAGs in the samples is then determined by comparing the OD of the samples to the standard curve. |
| Product Name | Clicks |
|---|---|
| 小鼠血管内皮生长因子C(VEGF-C)ELISA试剂盒 | 2407 |
| 小鼠血管生成素1(ANG-1)ELISA试剂盒 | 2451 |
| 小鼠血管生成素2(ANG-2)ELISA试剂盒 | 2141 |
| 小鼠血管生成素4(ANG-4)ELISA试剂盒 | 1856 |
| 小鼠血管性血友病因子(vWF)ELISA试剂盒 | 2222 |
| 小鼠血小板生成素(TPO)ELISA试剂盒 | 1926 |
| 小鼠胰岛素(INS)ELISA试剂盒 | 2052 |
| 小鼠胰岛素样生长因子1(IGF-1)ELISA试剂盒 | 2088 |
| 小鼠胰岛素样生长因子2(IGF-2)ELISA试剂盒 | 1472 |
| 小鼠胰岛素样生长因子3(IGF-3)ELISA试剂盒 | 2077 |
| 小鼠胰岛素样生长因子结合蛋白1(IGFBP-1)ELISA试剂盒 | 2498 |
| 小鼠胰岛素样生长因子结合蛋白2(IGFBP-2)ELISA试剂盒 | 1805 |
| 小鼠胰岛素样生长因子结合蛋白-3(IGFBP-3)ELISA试剂盒 | 2407 |
| 小鼠胰岛素样生长因子结合蛋白4(IGFBP4)ELISA试剂盒 | 2210 |
| 小鼠胰岛素样生长因子结合蛋白5(IGFBP-5)ELISA试剂盒 | 2233 |
| 小鼠胰岛素样生长因子结合蛋白6(IGFBP-6)ELISA试剂盒 | 2674 |
| 小鼠胰岛素样生长因子结合蛋白7(IGFBP7)ELISA试剂盒 | 1881 |
| 小鼠胰岛素原(PI)ELISA试剂盒 | 2264 |
| 小鼠胰岛素自身抗体(IAA)ELISA试剂盒 | 1894 |
| 小鼠胰高血糖素(GC)ELISA试剂盒 | 2040 |